The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1-3 node positive breast cancer.

ABSTRACT:

Background

Oncotype DX testing has reduced the use of adjuvant chemotherapy in node-negative early breast cancer but less is known about its impact in node positive patients.

Aim

This study aimed to investigate the impact of Oncotype DX gene assay testing on the decision to offer adjuvant chemotherapy in oestrogen positive, human epidermal growth factor receptor 2 negative, 1-3 lymph node positive patients.

Methods

Retrospective review of all node positive patients who underwent Oncotype DX testing at a single centre. Clinicopathological data, as well as estimated survival benefit data (from the PREDICT tool), was evaluated by a multidisciplinary group of surgeons and oncologists. Treatment decisions based on clinicopathological data were compared to recurrence scores

SUBMITTER: Malam Y 

PROVIDER: S-EPMC9351646 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature